How is Pomalyst used?
Pomalyst® (pomalidomide, Celgene) works in multiple ways to slow or kill myeloma cells. Recently it has been shown in studies the MMRC helped to fund that Pomalyst and other IMiDs bind a protein in myeloma cells called cereblon. This binding triggers myeloma cell death. In some studies higher levels of cereblon are associated with better outcomes after treatment. Pomalyst is also known to stimulate the immune system and to affect the blood vessels and other substances surrounding a tumor (known as the tumor microenvironment) which help to feed the cancer cell’s growth.
What types of patients can benefit from Pomalyst?
Pomalyst has been shown to be effective in patients with relapsed and refractory multiple myeloma following multiple lines of treatment with other available agents, including Velcade and Revlimid.
In addition, Pomalyst is effective in patients with high-risk myeloma as well as those with kidney problems.